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 Evaluation  Assessment  TreatmentErectile dysfunction (ED) was defined by the National Institutes of Health Consensus
Development Panel on Impotence as the persistent inability to attain and maintain
an erection sufficient for sexual intercourse.1 ED is the most thoroughly studied sexual
dysfunction in men and the most common sexual complaint of men presenting to their
health care providers.2 Various large-scale studies (both cross-sectional and longitu-
dinal) have indicated that the worldwide prevalence of ED is between 10% and 20%.
ED is strongly correlated with aging, with a steep incline in prevalence rates, from
6.5% in men aged 20 to 39 years to 77.5% in those aged 75 years and older.3 ED
is also associated with various comorbidities, including psychological factors, cardio-
vascular diseases, diabetes mellitus, and metabolic syndrome, and with smoking.4
Iatrogenic ED is not uncommon and can be the result of pelvic surgical procedures
or the use of various medications.4
Although ED is not a direct threat to physical health, it can have dramatic effects on
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Albersen et al202patients and their sexual partners. ED is also an independent predictor of cardiovas-
cular morbidity and mortality.5,6 For these reasons, ED merits consideration from the
primary care physician as an important health concern and as a potential sentinel
event for serious health problems. This article discusses the physiology and patho-
physiology of erectile function in men, how the primary care physician may address
the clinical problem of ED in practice, and when specialty referral is indicated.PHYSIOLOGY AND PATHOPHYSIOLOGY OF ED
Penile erection is often described as a neurovascular process that is controlled by
hormones. This article briefly describes the physiologic mechanisms of penile erec-
tion. A more elaborate discussion of the mechanisms of penile erection can be found
elsewhere.4,7,8
Physiology of Penile Erection
During sexual stimulation, the hypothalamus is exposed to input from various
neurotransmitters; dopamine seems to be the primary erectogenic central nervous
system neurotransmitter. Dopamine-containing nerve endings impinge on oxytocinergic
cell bodies contained in pathways descending from the hypothalamus to the brain stem
and spinal autonomic centers and produce a “psychogenically mediated” erection.8 A
“tactile-mediated” erectogenic stimulus may result from direct stimulation of the penis.
This stimulus occurs via sensory neurons that synapse in the sacral spinal cord.
In either case, the cavernous nerves, which arise from the pelvic plexus, are directly
responsible for conducting impulses that generate penile erection. These nerves run
alongside the posterolateral side of the prostatic capsule and perforate the urogenital
diaphragm to enter the cavernous bodies at the level of the crura. Cavernous nerve
activation leads to the release of the gaseous neurotransmitter nitric oxide (NO)
from the nonadrenergic, noncholinergic nerve terminals in the corpus cavernosum.
Additional NO is released from the endothelium in response to shear stress and the
release of acetylcholine from parasympathetic endothelial nerve endings. In both
cases, NO is synthesized by the enzyme nitric oxide synthase (NOS), which converts
oxygen and l-arginine to NO and citrulline in the cavernous nerve terminals (nNOS) and
in the endothelium (eNOS).4,7,8
NO passively diffuses into smooth muscle cells in the arterial wall and the trabeculae
of the corpus cavernosum, where it binds to and activates soluble guanylate cyclase
(GC). GC then catalyzes the breakdown of guanosine triphosphate into 3’5’-cyclic
guanosine monophosphate (cGMP). cGMP acts as a downstream messenger and
initiates a chain of reactions ultimately resulting in a decrease of intracellular calcium
and relaxation of the smooth muscle (Fig. 1). Although this pathway is functionally the
most important means to produce smooth muscle relaxation, it is supported by the
synergistic actions of other pathways using 3’5’-cyclic adenosine monophosphate
(cAMP) as a second messenger.
cAMP and cGMP are hydrolyzed by a class of enzymes called phosphodiesterases,
of which subtype 5 (PDE5), a cGMP-specific phosphodiesterase, seems to be the
dominant active isoform in penile tissue. Vasodilation and relaxation of trabecular
smooth muscle allow rapid blood flow into the cavernosal sinusoids and the
development of an erection, which is maintained by the compression of subtunical
venules against the tunica albuginea, and reinforced by contraction of the voluntary
ischiocavernosus muscle during the rigid erection phase. These pro-erectogenic
parasympathetic pathways are counterbalanced by several sympathetically mediated
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this review and are discussed in detail elsewhere.4,9
Pathophysiology of ED
Penile erection requires neural transmission of pro-erectile impulses, an intact arterial
blood supply, and functional erectile tissue in the corpus cavernosum. ED can develop
from a defect in one of these tissues or, more commonly, from a defect in a combination
of tissues. ED is classified as vasculogenic, neurogenic, hormonal, anatomic/structural,
drug-induced, or psychogenic.4,10Table 1 summarizes themost prevalent causes ofED.
ED is strongly associated with various comorbidities, including cardiovascular
diseases, diabetes mellitus, metabolic syndrome, and late-onset hypogonadism,
and with smoking.8 Aging is another major risk factor for ED.11 These comorbid condi-
tions and their relationship with ED will be discussed more in detail in the article by
Berookhim and Bar-Chama elsewhere in this issue.ASSESSMENT OF ED
Medical History
ED isoftenmultifactorial in origin and is thereforebestmanagedwith aholistic approach
that includes lifestyle modification, pharmacologic treatment, and attention to the rela-
tionship between partners. It is of particular importance to encourage open and honest
communication between the patient and partner. All of these approaches are best facil-
itated in the context of a trusting patient/provider relationship, and therefore providers
must establish rapport with patients when addressing issues of sexuality.10,11
The initial evaluation of ED should include a complete medical, psychosocial, and
sexual history. A thorough medical assessment is mandatory in evaluating erectile
complaints, particularly in older men and patients at intermediate and high risk for
cardiovascular disease.10 These patients should undergo cardiovascular assessment
before continuing sexual activity and before beginning therapy for ED (Fig. 2).12 Signs
and symptoms of possible underlying conditions should be assessed, such as depres-
sion, diabetes, late-onset hypogonadism, metabolic syndrome, andmedication/surgi-
cally induced causes of ED. Information about the association between ED and
tobacco use can be an important tool in helping patients decide to quit use of tobacco
products.10,13 A thorough review of current medications may reveal agents that are
known to cause or exacerbate ED (eg, antidepressants, antiandrogens, thiazides,
and b-blockers). It is also important to assess for use of nitrate-donors, which are
absolute contraindications for therapy with PDE5 inhibitors, and a-blockers that
require an interval between use of the two drugs.10,14 The goal of the history should
be to not only understand the specific erectile condition but also identify possible
underlying and reversible or treatable disorders.
Sexual History
The use of validated questionnaires, such as the International Index of Erectile Func-
tion, can be useful as an “ice-breaker” to initiate the conversation about ED. Numeric
scores from instruments such as this may also be helpful in assessing the severity of
ED, screening for other sexual dysfunctions, and evaluating treatment outcome.15,16
These metrics ,however, should not be regarded as a replacement for direct assess-
ment of sexual history.13 An adequate sexual history should include information about
current sexual relationships, the emotional status of the patient and the partner, and
the exact nature of the couple’s sexual concerns.10 Issues of sexual orientation
and gender identity should also be noted.13 Descriptive measures such as rigidity
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sexual arousal should be discussed, because they can give clues about the cause of
ED. The onset of the problem and any situational factors that ameliorate or exacerbate
ED should be determined. Problems with arousal, ejaculation, and difficulty reaching
orgasm should be discussed because these may be signs of concomitant sexual
dysfunctions requiring specialist assessment.10 The impact of ED and other sexual
dysfunctions on general well-being and sexual satisfaction, and issues of partner
interest in and satisfaction with sex should be discussed.
Physical Examination
A complete external genital examination should be performed to detect anatomic or
structural deformities of the penis, such as Peyronie plaques. Assessment of testicular
size is important because small testes and regression of secondary sex characteristics
may indicate hypogonadism.10,11,13 Physical examination should also include a general
screening for risk factors andcomorbidities that are associatedwithED, suchascardio-
vascular disease, neurologic disease, and obesity. Blood pressure and heart rate
should be measured if they were not assessed in the previous 3 to 6 months.10
Laboratory Testing
Recommended laboratory tests include a complete blood cell count and measure-
ments of fasting serum glucose, a lipid profile, and free and total testosterone, partic-
ularly in patients with signs of hypogonadism.10,11,13 Additional hormonal testing is
only required when low testosterone levels are detected. Baseline prostate-specific
antigen screening is advised in patients older than 40 years or when ED is accompa-
nied by lower urinary tract symptoms.17
Specific Diagnostic Testing
Radiologic testing, nocturnal penile rigidity testing, vascular and neurologic functional
testing, and penile Doppler ultrasound are available for further diagnostic workup of
ED. These tests are not routinely indicated in the primary care setting but may be
ordered by urologists or sexual medicine specialists in certain cases.4,10Fig. 1. Molecular mechanisms of penile smooth muscle relaxation. Nitric oxide (NO) is
released from nerve terminals in the corpus cavernosum in response to a neural stimulus
and from the endothelium in response to the release of acetylcholine (Ach) and the shear
stress elicited by increased blood flow in the corporeal sinusoids. NO binds to soluble gua-
nylate cyclase (sGC) and thereby activates this enzyme, which catalyzes the breakdown of
guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). Other path-
ways, which are initiated by vasoactive intestinal polypeptide and prostaglandin E1, activate
a G protein (G)–coupled receptor, leading to activation of adenylate cyclase (AC), which
catalyzes the breakdown of adenosine triphosphate (ATP) into cyclic adenosine monophos-
phate (cAMP). cGMP and cAMP exert analogous effects by activating protein kinase G and A
(PK G/A), respectively, which modulate potassium and calcium channels in the cell
membrane and the inositol triphosphate receptor (IP3-R) and the calcium-ATPase pump in
the membrane of the sarcoplasmic reticulum (SR). These events lead to a lowering of the
cytosolic calcium concentration, which causes dissociation of calcium from calmodulin.
Calmodulin then dissociates from myosin light chain kinase, thus inactivating it, leading
to smooth muscle relaxation and ultimately penile tumescence. eNOS, endothelial nitric
oxide synthase; NOS, neuronal nitric oxide synthase; PDE, phosphodiesterase; VIP, vasoactive
intestinal polypeptide. (Adapted from Albersen M, Shindel AW, Mwamukonda KB, et al. The
future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opin
Emerg Drugs 2010;15:467–80; with permission from Informa Healthcare.)
Table 1
Pathophysiology of ED
Classification Causes
Vasculogenic Cardiovascular disease, atherosclerosis
Hypertension
Diabetes mellitus
Hyperlipidemia
Smoking
Major surgery (retroperitoneum)
Radiotherapy (retroperitoneum)
Neurogenic-central causes Multiple sclerosis
Multiple atrophy
Parkinson disease
Tumors
Stroke
Disk disease
Spinal cord disorders
Neurogenic-peripheral causes Diabetes mellitus
Alcoholism
Uremia
Polyneuropathy
Surgery (pelvis or retroperitoneum, radical prostatectomy)
Anatomic/structural Peyronie disease
Penile fibrosis (after pelvic radiotherapy or pelvic surgery)
Penile trauma (penile fracture)
Congenital curvature of the penis
Micropenis
Hypospadias, epispadias
Hormonal Primary hypogonadism (eg, late-onset hypogonadism)
Secondary hypogonadism/hypogonadotropic
hypogonadism (eg, hyperprolactinemia)
Hyper- and hypothyroidism
Cushing disease
Drug- or substance-induced Antihypertensives (thiazides and ß-blockers are most
common)
Antidepressants
Antipsychotics
Antiandrogens
Antihistamines
Recreational drugs/smoking
Psychogenic Generalized type (eg, lack of arousability, disorders of
sexual intimacy)
Situational type (eg, partner-related, performance-related
issues, from distress)
Adapted from Wespes E , Amar E, Eardley I, et al. EAU Guidelines on Male Sexual Dysfunction:
erectile dysfunction and premature ejaculation.  European Association of Urology 2009; with
permission.
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The decision of when to refer a patient for management of ED must be made on
a case-by-case basis and is determined in large part by the interest and comfort
a given primary care provider has in managing ED. Cases that should prompt imme-
diate referral include patients with lifelong ED, a history of pelvic, urethral or perineal
Sexual Inquiry
Clinical
Evaluation
Cardiovascular
Assessment and
Restratification
Risk FX and CHD Evaluation, Treatment and Follow up for all patients with ED
Low Risk High Risk
Indeterminate
Risk
Initiate or resume
sexual activity
or
Treat for sexual
dysfunction
Sexual activity
deferred until
cardiac condition
is stabilized
Fig. 2. Sexual dysfunction and cardiac risk (the second Princeton Consensus Conference).
CHD, coronary heart disease; Fx, risk factors. (Reprinted from Kostis JB, Jackson G, Rosen
R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).
Am J Cardiol 2005;96(2):313–21.  2005; with permission from Elsevier.)
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testing, and complex or severe psychiatric or psychosexual disorders.10TREATMENT OF ED IN THE PRIMARY CARE SETTING
General Considerations Before Initiating Pharmacologic Treatment
Both the patient’s and partner’s understanding of ED and results of the diagnostic
tests should be reviewed before treatment is initiated, so that a rational selection of
treatment options and expectations can be provided. Current pharmacologic treat-
ments for ED do not cure ED but can generally be relied on to greatly improve erectile
function. Setting realistic treatment goals and granting permission and legitimacy for
engaging in alternative means of sexual intimacy that do not rely on penetrative sexual
intercourse should be a goal of therapy. Few older patients with ED will be able to
regain full potency, but most should be able to experience restoration of satisfying
sexual encounters.
Underlying reversible conditions (obesity, medical comorbidities, relationship
issues) should be addressed and treated before or simultaneously with initiating
specific ED-directed treatment.18 Lifestyle changes, such as exercise and smoking
cessation, should be suggested where applicable. Referral to exercise physiologists,
nutritionists, or personal trainers may be of some benefit in these situations.
Albersen et al208Oral Pharmacotherapy
Although many treatment modalities are available for ED, this article mainly focuses on
oral pharmacotherapy, which will efficiently treat most patients experiencing ED.
When oral therapies fail, referral to a specialist should be considered except when
the primary care provider has a particular interest and comfort in dealing with sexuality
issues.
PDE5-specific inhibitors
PDE5-specific inhibitors (PDE5Is) are nonhydrolyzable analogs of cGMP and exert
their beneficial effects on smooth muscle relaxation through competitively binding
to the catalytic site of PDE5. Through slowing the degradation of cGMP, these drugs
produce an intracellular accumulation of cGMP in smooth muscle cells in the arteries
and trabeculae of the corpus cavernosum (see Fig. 1), resulting in relaxation of the
smooth muscle, increased arterial blood flow, and penile tumescence.19
Treatment of ED with PDE5I
In current treatment guidelines, PDE5Is are recommended as the preferred pharmaco-
therapy for ED.10 Numerous trials have established on-demand efficacy rates of 60%
to 70% in the general population, and postmarketing data confirms excellent safety
profiles of the three compounds currently available in the United States (sildenafil, var-
denafil, and tadalafil).19–22 Although a large crossover study showed an overall equiv-
alence in the subjective perception of treatment benefits among all PDE5Is, the three
currently available drugs differ from each other in time to onset of action and duration
of action (sildenafil and vardenafil up to 5 hours and tadalafil up to 24–36 hours).23 The
choice of appropriate drug is based on patient and partner preference guided by
physician advice.20
Before initiation of treatment, patients should be informed that sexual stimulation is
essential for the efficacy of the drugs. Although somemenmay experience limited effi-
cacy after a first trial, these patients should be informed that results generally improve
with repeated dosing, and a minimum of six attempts should be made before treat-
ment is considered a failure. The recommended starting doses are 50 mg for sildenafil
and 10 mg for vardenafil and tadalafil. The unique pharmacokinetic properties of tada-
lafil have led to the approval of this drug as a daily treatment for ED at 2.5- and 5-mg
doses; this regimen may be best for patients who have frequent intercourse or those
who desire to separate the act of taking the drug from sexual interactions. The lowest
therapeutic doses (25 mg of sildenafil and 5 mg of vardenafil and tadalafil on-demand)
should be used when liver or kidney failure is present or when the patient uses medi-
cation that inhibits the CYP34A pathway. Examples of these drugs are ketoconazole,
itraconazole, erythromycin, clarithromycin, and HIV protease inhibitors.10 However,
patients taking medications that potentiate the CYP34A pathway, such as rifampin,
phenobarbital, phenytoin, and carbamazepine, may need higher doses for efficacy.10
Safety profile
Postmarketing surveillance has not shown increased myocardial infarction rates in
patients using PDE5Is compared with age-matched controls.21 However, certain
heart-related precautions must be considered in men taking PDE5Is. PDE5Is are rela-
tively contraindicated in patients with unstable angina pectoris, recent myocardial
infarction, certain arrhythmias, and poorly controlled hypertension. These patients
shouldundergocardiovascular examination and treatment for their heart-relatedcondi-
tion before initiating ED treatment.10 Furthermore, patients treated with nitrates or
nitrate-donors should not take PDE5Is, and, use of PDE5Is with certain a-blockers
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or blood pressure control should take PDE5IS with at least a 4-hour window between
dosing because of a theoretical risk of orthostatic hypotension, although some
evidence suggests that the risk is low in patients on long-term a-blocker therapy.14
Patients with prolongation of the QTc interval should not be treated with vardenafil.22
Adverse events
The most common adverse events from PDE5Is include headache, facial and ocular
hyperemia, nasal congestion, myalgia, dyspepsia, and back pain. These side effects
are attributable to specific inhibition of PDE5 and subsequent vasodilatation in tissues
other than the penis.7,21 Congestion and flushing are more common with sildenafil
relative to the other PDE5Is, whereas myalgias and dyspepsia are more strongly asso-
ciated with tadalafil and vardenafil, respectively. Other less-common adverse events
involve visual disturbances, most often attributable to the inhibition of PDE6 in the
cones of the retina.7 Adverse events account for approximately 25% of patients
who discontinue PDE5I use, whereas the most common reason for discontinuation
of PDE5Is is lack of efficacy.24 More serious adverse events are rare and include
seizures, nonarteritic ischemic optic neuritis, and acute hearing loss, although the
exact role of PDE5Is in these conditions is debatable and reports are anecdotal.21,25
Patients can generally be reassured that the risk of serious long-term adverse events
is low in appropriately selected candidates for PDE5I therapy.
Nonresponders
Of the patients who do not experience an initial response to PDE5I, between 30% and
50% may be converted to responders through re-education on proper dosing tech-
nique and through dose-escalation. Patients who discontinue tadalafil because of
side effects may benefit from the daily-dosing option (2.5 or 5 mg/d).26–28 Further-
more, addition of exogenous testosterone supplementation may enhance PDE5I
therapy in individuals in whom hypogonadism is confirmed.29 Because the efficacy
of PDE5I depends on the integrity of the NO pathway in producing cGMP, patients
in whom this pathway is disturbed will benefit far less from PDE5I treatment compared
with the general population. Disease states that diminish NO availability include dener-
vation of the erectile tissue after radical prostatectomy; severe diabetes; and down-
regulation of NOS expression, as may be seen in atherosclerosis, metabolic
syndrome, aging, and hypogonadism.7 These difficult-to-treat patients benefit from
referral to a sexual medicine specialist or urologist for second-line treatment.
Alternative Oral Pharmacotherapy
Apomorphine SL
Apomorphine is a centrally acting nonselective dopamine agonist that exhibits D2-like
effects. It acts by binding to dopamine receptors in the hypothalamus and enhances
naturally occurring pro-erectile signals.30 It is available in 2- or 3-mg doses but has not
been approved in the United States for the treatment of ED.19 It is rapidly absorbed
through the sublingual route of administration and results in the development of an
erection within 20 minutes in more than two-thirds of patients.30 Apomorphine has
lower efficacy and satisfaction rates than PDE5Is, and is most effective in patients
with mild to moderate ED.10 It also is a valid alternative to PDE5Is for patients in
whom psychogenic ED is suspected and in those who have contraindications to
PDE5Is, such as those taking nitrates. The most common adverse events are caused
by nonspecific binding to other subtypes of the dopamine receptor and include
nausea, headache, and dizziness.30 These effects occur with relative high frequency,
and have limited the usefulness of this drug.
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Yohimbine is a natural peripherally and centrally acting a-blocker. However, little
evidence shows its efficacy in treating ED, and therefore it is not currently recommended
inmost guidelines formanagement of ED. Itmayhave a role inpatientswhoprefer natural
products but should not be considered a recommendedmainstreammedical therapy.10
Vacuum Constriction Devices
The vacuum constriction device (VCD) creates negative pressure around the penis,
thereby initiating passive engorgement of the sinusoidal spaces and creating an erec-
tion. Maintenance of erection is facilitated by application of a rubber cuff worn around
the base of the penis. Although effective in up to 90% of patients, the use of a vacuum
device might be perceived as disruptive, especially by younger men.10 Local side
effects are relatively minor and include bruising, some discomfort, and ejaculatory
obstruction. It is advised to limit the use of the constriction band to 30 minutes to avoid
skin necrosis. Contraindications to VCD use include bleeding disorders and the use of
anticoagulants.10
Second-Line Treatment
Intracavernous and intraurethral therapy
Before the advent of PDE5I,s intracavernous and intraurethral administration were the
only nonsurgical treatment options for ED. The most commonly used substance, and
currently the only one approved by the U.S. Food and Drug Administration as a treat-
ment of ED, is prostaglandin E1 (PGE1). PGE1 activates adenylate cyclase and thereby
raises intracellular cAMP, with effects analogous to those of cGMP (see Fig. 1). These
effects are independent of the NO-cGMP pathway, making this treatment an excellent
option for patientswhodonot experience response toPDE5I therapy.31 Intracavernous
PGE1 therapy has an overall satisfaction rate of approximately 80%.32
Phentolamine, papaverine, and vasoactive intestinal peptide are also available for
intracavernous injection, although their role is limited to combination therapy
(commonly referred to as bimix or trimix).11 PGE1 is also available for intraurethral
administration (medicated urethral system for erection [MUSE]).
Adverse events from these therapies include priapism, variable degrees of pain with
injection in approximately half of patients, and penile fibrosis after long-term use.31
Patients are advised to consult their physician if they experience prolonged penile
pain or an erection lasting up to or more than 4 hours, because aspiration of cavernous
blood may be necessary for penile decompression.10 Relative contraindications to
injection therapy include a history of priapism or bleeding disorders. Before initiation
of therapy, patients follow a short in-office training program. MUSE has many side
effects in commonwith intracavernous PGE1, although it is less likely to cause priapism
and may have marginal efficacy in many cases. MUSE has also been associated with
hypotension, syncope, urethral burning or pain, and vaginal irritation in the partner.31
Third-Line Therapy (Surgery)
Implantation of a penile prosthesis, which can be either inflatable or malleable, is indi-
cated for men in whom pharmacologic therapy is not effective. Implantation of a penile
prosthesis has satisfaction rates of 70% to 90%, but patients should be aware of the
definitive and irreversible nature of this surgery.10 Adverse events include mechanical
failure after several years of use (50% after a 10-year interval), infection (1%–3%), and,
rarely, erosion.10,11
Other surgical options available for ED include penile revascularization and venous
ligation. Outcomes of these surgeries in the general population of patients with ED are
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patients and should be performed in specialized centers only.10,11SUMMARY
ED is a prevalent and important disease that has been associated with various comor-
bidities. The evaluation of patients with ED should include a general health assess-
ment followed by a discussion of reversible factors and lifestyle changes that might
help preserve erectile capacity. Numerous effective treatment options are currently
available. A frank discussion about use and side effects of these therapies is required
to optimize success. Although oral pharmacologic treatments can be initiated and
monitored by the primary care physician, patients who do not experience response
to these treatments may be best served by referral to a sexual medicine specialist
for further assessment and consideration of other treatment options.REFERENCES
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